STVN
Stevanato Group SpA
NYSE · Healthcare · Medical - Instruments & Supplies · IT
$21.70
−4.28%Year over year
Reported trailing growth
- Revenue
- +6.7%
- EBITDA
- -12.3%
- EBIT
- +6.9%
- EPS
- -4.0%
- Free cash flow
- +82.1%
- Operating cash flow
- -17.8%
Forward estimates
Based on analyst estimates
- Revenue
- +9.1%
- EBITDA
- +42.1%
- EPS
- +38.9%
Three-year CAGR
- Revenue
- +5.0%
- EBITDA
- +4.0%
- EBIT
- -1.6%
- Net income
- -2.0%
- EPS
- -2.6%
- Free cash flow
- +113.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026